Activation of the NOTCH pathway in head and neck cancer

Wenyue Sun, Daria Gaykalova, Michael F. Ochs, Elizabeth Mambo, Demetri Arnaoutakis, Yan Liu, Myriam Loyo, Nishant Agrawal, Jason Howard, Ryan Li, Sun Ahn, Elana Fertig, David Sidransky, Jeffery Houghton, Kalyan Buddavarapu, Tiffany Sanford, Ashish Choudhary, Will Darden, Alex Adai, Gary LathamJustin Bishop, Rajni Sharma, William H. Westra, Patrick Hennessey, Christine H. Chung, Joseph A. Califano

Research output: Contribution to journalArticle

Abstract

NOTCH1 mutations have been reported to occur in 10% to 15% of head and neck squamous cell carcinomas (HNSCC). To determine the significance of these mutations, we embarked upon a comprehensive study of NOTCH signaling in a cohort of 44 HNSCC tumors and 25 normal mucosal samples through a set of expression, copy number, methylation, and mutation analyses. Copy number increases were identified in NOTCH pathway genes, including the NOTCH ligand JAG1. Gene set analysis defined a differential expression of the NOTCH signaling pathway in HNSCC relative to normal tissues. Analysis of individual pathway-related genes revealed overexpression of ligands JAG1 and JAG2 and receptor NOTCH3. In 32% of the HNSCC examined, activation of the downstream NOTCH effectors HES1/HEY1 was documented. Notably, exomic sequencing identified 5 novel inactivating NOTCH1 mutations in 4 of the 37 tumors analyzed, with none of these tumors exhibiting HES1/HEY1 overexpression. Our results revealed a bimodal pattern of NOTCH pathway alterations in HNSCC, with a smaller subset exhibiting inactivating NOTCH1 receptor mutations but a larger subset exhibiting other NOTCH1 pathway alterations, including increases in expression or gene copy number of the receptor or ligands as well as downstream pathway activation. Our results imply that therapies that target the NOTCH pathway may be more widely suitable for HNSCC treatment than appreciated currently.

Original languageEnglish (US)
Pages (from-to)1091-1104
Number of pages14
JournalCancer Research
Volume74
Issue number4
DOIs
StatePublished - Feb 15 2014

Fingerprint

Head and Neck Neoplasms
Mutation
Ligands
Genes
Neoplasms
Gene Dosage
Methylation
Carcinoma, squamous cell of head and neck

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sun, W., Gaykalova, D., Ochs, M. F., Mambo, E., Arnaoutakis, D., Liu, Y., ... Califano, J. A. (2014). Activation of the NOTCH pathway in head and neck cancer. Cancer Research, 74(4), 1091-1104. https://doi.org/10.1158/0008-5472.CAN-13-1259

Activation of the NOTCH pathway in head and neck cancer. / Sun, Wenyue; Gaykalova, Daria; Ochs, Michael F.; Mambo, Elizabeth; Arnaoutakis, Demetri; Liu, Yan; Loyo, Myriam; Agrawal, Nishant; Howard, Jason; Li, Ryan; Ahn, Sun; Fertig, Elana; Sidransky, David; Houghton, Jeffery; Buddavarapu, Kalyan; Sanford, Tiffany; Choudhary, Ashish; Darden, Will; Adai, Alex; Latham, Gary; Bishop, Justin; Sharma, Rajni; Westra, William H.; Hennessey, Patrick; Chung, Christine H.; Califano, Joseph A.

In: Cancer Research, Vol. 74, No. 4, 15.02.2014, p. 1091-1104.

Research output: Contribution to journalArticle

Sun, W, Gaykalova, D, Ochs, MF, Mambo, E, Arnaoutakis, D, Liu, Y, Loyo, M, Agrawal, N, Howard, J, Li, R, Ahn, S, Fertig, E, Sidransky, D, Houghton, J, Buddavarapu, K, Sanford, T, Choudhary, A, Darden, W, Adai, A, Latham, G, Bishop, J, Sharma, R, Westra, WH, Hennessey, P, Chung, CH & Califano, JA 2014, 'Activation of the NOTCH pathway in head and neck cancer', Cancer Research, vol. 74, no. 4, pp. 1091-1104. https://doi.org/10.1158/0008-5472.CAN-13-1259
Sun W, Gaykalova D, Ochs MF, Mambo E, Arnaoutakis D, Liu Y et al. Activation of the NOTCH pathway in head and neck cancer. Cancer Research. 2014 Feb 15;74(4):1091-1104. https://doi.org/10.1158/0008-5472.CAN-13-1259
Sun, Wenyue ; Gaykalova, Daria ; Ochs, Michael F. ; Mambo, Elizabeth ; Arnaoutakis, Demetri ; Liu, Yan ; Loyo, Myriam ; Agrawal, Nishant ; Howard, Jason ; Li, Ryan ; Ahn, Sun ; Fertig, Elana ; Sidransky, David ; Houghton, Jeffery ; Buddavarapu, Kalyan ; Sanford, Tiffany ; Choudhary, Ashish ; Darden, Will ; Adai, Alex ; Latham, Gary ; Bishop, Justin ; Sharma, Rajni ; Westra, William H. ; Hennessey, Patrick ; Chung, Christine H. ; Califano, Joseph A. / Activation of the NOTCH pathway in head and neck cancer. In: Cancer Research. 2014 ; Vol. 74, No. 4. pp. 1091-1104.
@article{edef066ca42e40c59172ed63845cbdb4,
title = "Activation of the NOTCH pathway in head and neck cancer",
abstract = "NOTCH1 mutations have been reported to occur in 10{\%} to 15{\%} of head and neck squamous cell carcinomas (HNSCC). To determine the significance of these mutations, we embarked upon a comprehensive study of NOTCH signaling in a cohort of 44 HNSCC tumors and 25 normal mucosal samples through a set of expression, copy number, methylation, and mutation analyses. Copy number increases were identified in NOTCH pathway genes, including the NOTCH ligand JAG1. Gene set analysis defined a differential expression of the NOTCH signaling pathway in HNSCC relative to normal tissues. Analysis of individual pathway-related genes revealed overexpression of ligands JAG1 and JAG2 and receptor NOTCH3. In 32{\%} of the HNSCC examined, activation of the downstream NOTCH effectors HES1/HEY1 was documented. Notably, exomic sequencing identified 5 novel inactivating NOTCH1 mutations in 4 of the 37 tumors analyzed, with none of these tumors exhibiting HES1/HEY1 overexpression. Our results revealed a bimodal pattern of NOTCH pathway alterations in HNSCC, with a smaller subset exhibiting inactivating NOTCH1 receptor mutations but a larger subset exhibiting other NOTCH1 pathway alterations, including increases in expression or gene copy number of the receptor or ligands as well as downstream pathway activation. Our results imply that therapies that target the NOTCH pathway may be more widely suitable for HNSCC treatment than appreciated currently.",
author = "Wenyue Sun and Daria Gaykalova and Ochs, {Michael F.} and Elizabeth Mambo and Demetri Arnaoutakis and Yan Liu and Myriam Loyo and Nishant Agrawal and Jason Howard and Ryan Li and Sun Ahn and Elana Fertig and David Sidransky and Jeffery Houghton and Kalyan Buddavarapu and Tiffany Sanford and Ashish Choudhary and Will Darden and Alex Adai and Gary Latham and Justin Bishop and Rajni Sharma and Westra, {William H.} and Patrick Hennessey and Chung, {Christine H.} and Califano, {Joseph A.}",
year = "2014",
month = "2",
day = "15",
doi = "10.1158/0008-5472.CAN-13-1259",
language = "English (US)",
volume = "74",
pages = "1091--1104",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Activation of the NOTCH pathway in head and neck cancer

AU - Sun, Wenyue

AU - Gaykalova, Daria

AU - Ochs, Michael F.

AU - Mambo, Elizabeth

AU - Arnaoutakis, Demetri

AU - Liu, Yan

AU - Loyo, Myriam

AU - Agrawal, Nishant

AU - Howard, Jason

AU - Li, Ryan

AU - Ahn, Sun

AU - Fertig, Elana

AU - Sidransky, David

AU - Houghton, Jeffery

AU - Buddavarapu, Kalyan

AU - Sanford, Tiffany

AU - Choudhary, Ashish

AU - Darden, Will

AU - Adai, Alex

AU - Latham, Gary

AU - Bishop, Justin

AU - Sharma, Rajni

AU - Westra, William H.

AU - Hennessey, Patrick

AU - Chung, Christine H.

AU - Califano, Joseph A.

PY - 2014/2/15

Y1 - 2014/2/15

N2 - NOTCH1 mutations have been reported to occur in 10% to 15% of head and neck squamous cell carcinomas (HNSCC). To determine the significance of these mutations, we embarked upon a comprehensive study of NOTCH signaling in a cohort of 44 HNSCC tumors and 25 normal mucosal samples through a set of expression, copy number, methylation, and mutation analyses. Copy number increases were identified in NOTCH pathway genes, including the NOTCH ligand JAG1. Gene set analysis defined a differential expression of the NOTCH signaling pathway in HNSCC relative to normal tissues. Analysis of individual pathway-related genes revealed overexpression of ligands JAG1 and JAG2 and receptor NOTCH3. In 32% of the HNSCC examined, activation of the downstream NOTCH effectors HES1/HEY1 was documented. Notably, exomic sequencing identified 5 novel inactivating NOTCH1 mutations in 4 of the 37 tumors analyzed, with none of these tumors exhibiting HES1/HEY1 overexpression. Our results revealed a bimodal pattern of NOTCH pathway alterations in HNSCC, with a smaller subset exhibiting inactivating NOTCH1 receptor mutations but a larger subset exhibiting other NOTCH1 pathway alterations, including increases in expression or gene copy number of the receptor or ligands as well as downstream pathway activation. Our results imply that therapies that target the NOTCH pathway may be more widely suitable for HNSCC treatment than appreciated currently.

AB - NOTCH1 mutations have been reported to occur in 10% to 15% of head and neck squamous cell carcinomas (HNSCC). To determine the significance of these mutations, we embarked upon a comprehensive study of NOTCH signaling in a cohort of 44 HNSCC tumors and 25 normal mucosal samples through a set of expression, copy number, methylation, and mutation analyses. Copy number increases were identified in NOTCH pathway genes, including the NOTCH ligand JAG1. Gene set analysis defined a differential expression of the NOTCH signaling pathway in HNSCC relative to normal tissues. Analysis of individual pathway-related genes revealed overexpression of ligands JAG1 and JAG2 and receptor NOTCH3. In 32% of the HNSCC examined, activation of the downstream NOTCH effectors HES1/HEY1 was documented. Notably, exomic sequencing identified 5 novel inactivating NOTCH1 mutations in 4 of the 37 tumors analyzed, with none of these tumors exhibiting HES1/HEY1 overexpression. Our results revealed a bimodal pattern of NOTCH pathway alterations in HNSCC, with a smaller subset exhibiting inactivating NOTCH1 receptor mutations but a larger subset exhibiting other NOTCH1 pathway alterations, including increases in expression or gene copy number of the receptor or ligands as well as downstream pathway activation. Our results imply that therapies that target the NOTCH pathway may be more widely suitable for HNSCC treatment than appreciated currently.

UR - http://www.scopus.com/inward/record.url?scp=84894281594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894281594&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-1259

DO - 10.1158/0008-5472.CAN-13-1259

M3 - Article

C2 - 24351288

AN - SCOPUS:84894281594

VL - 74

SP - 1091

EP - 1104

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 4

ER -